Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

杜皮鲁玛 医学 安慰剂 慢性荨麻疹 内科学 双盲 随机对照试验 皮肤病科 相(物质) 特应性皮炎 病理 物理 量子力学 替代医学
作者
Marcus Maurer,Thomas B. Casale,Sarbjit S. Saini,Moshe Ben‐Shoshan,Ana M. Giménez‐Arnau,Jonathan A. Bernstein,Akiko Yagami,Aleksandra Stjepanovic,Allen Radin,Heribert Staudinger,Naimish Patel,Nikhil Amin,Bolanle Akinlade,Chunpeng Fan,Déborah Bauer,George D. Yancopoulos,Kiran Patel,Leda Mannent,Elizabeth Laws
出处
期刊:The Journal of Allergy and Clinical Immunology [Elsevier BV]
卷期号:154 (1): 184-194 被引量:118
标识
DOI:10.1016/j.jaci.2024.01.028
摘要

Graphical abstractAbstractBackgroundChronic spontaneous urticaria (CSU) is a chronic inflammatory disease characterized by recurrent pruritic wheals (hives) and/or angioedema. Patients with CSU could remain symptomatic despite standard-of-care H1 antihistamines (H1-AH) or anti-IgE (omalizumab) treatment. Dupilumab blocks IL-4/IL-13 signaling and is approved for multiple type 2/atopic indications.ObjectiveWe conducted two phase 3, randomized, placebo-controlled, double-blind trials comparing dupilumab with placebo in patients with symptomatic CSU despite H1-AH.MethodsIn LIBERTY-CSU CUPID Study A, patients were omalizumab-naive (n = 138, aged ≥6 years). In Study B, patients were omalizumab-intolerant/incomplete responders (n = 108, aged ≥12 years). The primary end point was either change from baseline over 7 days in the Urticaria Activity Score (UAS7) or Itch Severity Score (ISS7) at week 24, with the other as a key secondary end point, depending on regional regulatory requirements. Studies were pooled for safety assessment.ResultsIn Study A, UAS7 and ISS7 improved with dupilumab versus placebo (difference −8.5 [95% CI, −13.2 to −3.9; P = .0003] and −4.2 [95% CI, −6.6 to −1.8; P = .0005]). In Study B, tested at α = 0.043 after interim analysis, UAS7 improved (difference −5.8 [95% CI, −11.4 to −0.3; P = .0390]), with a numerical trend in ISS7 (difference −2.9 [95% CI, −5.7 to −0.07; nominal P = .0449, not significant]). Pooled safety data were consistent between dupilumab and placebo and with the known dupilumab safety profile.ConclusionsDupilumab reduced urticaria activity by reducing itch and hives severity in omalizumab-naive patients with CSU uncontrolled with H1-AH. Although the primary end point for Study B was not met, dupilumab effects were small in patients who were omalizumab-intolerant/incomplete responders.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
BrenhilD完成签到 ,获得积分10
1秒前
沙琪玛完成签到,获得积分10
1秒前
1秒前
星辰大海的应助被galioo3000采纳,获得10
1秒前
Juanjuan完成签到,获得积分10
1秒前
菜菜完成签到 ,获得积分10
2秒前
无奈狗完成签到,获得积分10
2秒前
上官若男的应助被米豆爸采纳,获得10
2秒前
当女遇到乔完成签到 ,获得积分0
3秒前
Jaaay发布了新的文献求助10
3秒前
何甜甜完成签到,获得积分10
3秒前
灿1980s完成签到,获得积分10
3秒前
zz完成签到,获得积分10
4秒前
余香的应助被LZ采纳,获得60
4秒前
彭于晏的应助被仙林AK47采纳,获得20
5秒前
夏至未至完成签到,获得积分10
5秒前
Lucas完成签到,获得积分10
5秒前
就喜欢喝百事完成签到,获得积分10
5秒前
欢呼天问完成签到,获得积分10
5秒前
舒庆春完成签到,获得积分10
5秒前
跳跃慕青完成签到,获得积分10
5秒前
腿毛怪大叔完成签到,获得积分10
5秒前
韩颖完成签到 ,获得积分10
5秒前
shxxy123完成签到 ,获得积分10
6秒前
局外人完成签到,获得积分10
6秒前
6秒前
这朵蘑菇完成签到,获得积分10
6秒前
蕤樾完成签到,获得积分10
6秒前
guohuameike完成签到,获得积分10
6秒前
虚幻凌晴完成签到,获得积分10
7秒前
英勇的飞凤完成签到,获得积分10
7秒前
7秒前
7秒前
机智的无心完成签到,获得积分10
7秒前
美菇完成签到 ,获得积分10
7秒前
MMM完成签到,获得积分10
7秒前
8秒前
李宏梅完成签到,获得积分10
8秒前
16601107082发布了新的文献求助10
8秒前
琉光完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166797
求助须知:如何正确求助?哪些是违规求助? 9559659
关于积分的说明 21751398
捐赠科研通 7757518
什么是DOI,文献DOI怎么找? 3429176
关于科研通互助平台的介绍 2553551
邀请新用户注册赠送积分活动 2473931